Cargando…

Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer

BACKGROUND: The aim of this study was to assess the diagnostic utility of metabolic parameters on fluorine-18-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/computed tomography (CT) for predicting lymph node (LN) metastasis in patients with cN2 non-small cell lung cancer (NSCLC). ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakanishi, Keita, Nakamura, Shota, Sugiyama, Tomoshi, Kadomatsu, Yuka, Ueno, Harushi, Goto, Masaki, Ozeki, Naoki, Fukui, Takayuki, Iwano, Shingo, Chen-Yoshikawa, Toyofumi Fengshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414769/
https://www.ncbi.nlm.nih.gov/pubmed/34474680
http://dx.doi.org/10.1186/s12885-021-08688-6
_version_ 1783747845091753984
author Nakanishi, Keita
Nakamura, Shota
Sugiyama, Tomoshi
Kadomatsu, Yuka
Ueno, Harushi
Goto, Masaki
Ozeki, Naoki
Fukui, Takayuki
Iwano, Shingo
Chen-Yoshikawa, Toyofumi Fengshi
author_facet Nakanishi, Keita
Nakamura, Shota
Sugiyama, Tomoshi
Kadomatsu, Yuka
Ueno, Harushi
Goto, Masaki
Ozeki, Naoki
Fukui, Takayuki
Iwano, Shingo
Chen-Yoshikawa, Toyofumi Fengshi
author_sort Nakanishi, Keita
collection PubMed
description BACKGROUND: The aim of this study was to assess the diagnostic utility of metabolic parameters on fluorine-18-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/computed tomography (CT) for predicting lymph node (LN) metastasis in patients with cN2 non-small cell lung cancer (NSCLC). METHODS: We retrospectively reviewed patients who underwent surgery for cN2 NSCLC between 2007 and 2020. Those who had clinically diagnosed positive hilar and mediastinal LNs by routine CT and PET/CT imaging were investigated. To measure the metabolic parameters of LNs, the data according to maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and LN-to-primary tumor ratio of SUVmax (LPR) were examined. The diagnosis of each retrieved LN was confirmed based on histopathological examination of surgical tissue specimens. Receiver operating characteristics (ROC) curves with area under the curve (AUC) calculations and multivariate analysis by logistic regression were performed. RESULTS: Forty-five patients with 84 clinically diagnosed positive hilar or mediastinal LNs were enrolled in the present study. Of the 84 LNs, 63 LNs were pathologically proven as positive (75%). The SUVmax, MTV, TLG, and LPR of LN metastasis were significantly higher than those of benign nodes. In the ROC analysis, the AUC value of LPR [AUC, 0.776; 95% confidence interval (CI), 0.640–0.913] was higher than that of LN SUVmax (AUC, 0.753; 95% CI, 0.626–0.880) or LN TLG3.5 (AUC, 0.746; 95% CI, 0.607–0.885). Using the optimal LPR cutoff value of 0.47, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 84.1, 66.7, 88.3, 58.3, and 79.8%, respectively. Multivariate analysis by logistic regression showed that LPR was an independent predictor for LN metastasis (odds ratio, 6.45; 95% CI, 1.785–23.301; P = 0.004). In the subgroup analysis of adenocarcinoma patients (n = 18; 32 LNs), TLG3.5 was a better predictor (AUC, 0.816; 95% CI, 0.639–0.985) than LPR (AUC, 0.792; 95% CI, 0.599–0.986) or LN SUVmax (AUC, 0.792; 95% CI, 0.625–0.959). CONCLUSIONS: Our findings suggest that LPR on FDG-PET is a useful predictor for LN metastasis in patients with cN2 NSCLC. TLG can be a good predictor for LN metastasis in patients with adenocarcinoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08688-6.
format Online
Article
Text
id pubmed-8414769
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84147692021-09-09 Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer Nakanishi, Keita Nakamura, Shota Sugiyama, Tomoshi Kadomatsu, Yuka Ueno, Harushi Goto, Masaki Ozeki, Naoki Fukui, Takayuki Iwano, Shingo Chen-Yoshikawa, Toyofumi Fengshi BMC Cancer Research BACKGROUND: The aim of this study was to assess the diagnostic utility of metabolic parameters on fluorine-18-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/computed tomography (CT) for predicting lymph node (LN) metastasis in patients with cN2 non-small cell lung cancer (NSCLC). METHODS: We retrospectively reviewed patients who underwent surgery for cN2 NSCLC between 2007 and 2020. Those who had clinically diagnosed positive hilar and mediastinal LNs by routine CT and PET/CT imaging were investigated. To measure the metabolic parameters of LNs, the data according to maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and LN-to-primary tumor ratio of SUVmax (LPR) were examined. The diagnosis of each retrieved LN was confirmed based on histopathological examination of surgical tissue specimens. Receiver operating characteristics (ROC) curves with area under the curve (AUC) calculations and multivariate analysis by logistic regression were performed. RESULTS: Forty-five patients with 84 clinically diagnosed positive hilar or mediastinal LNs were enrolled in the present study. Of the 84 LNs, 63 LNs were pathologically proven as positive (75%). The SUVmax, MTV, TLG, and LPR of LN metastasis were significantly higher than those of benign nodes. In the ROC analysis, the AUC value of LPR [AUC, 0.776; 95% confidence interval (CI), 0.640–0.913] was higher than that of LN SUVmax (AUC, 0.753; 95% CI, 0.626–0.880) or LN TLG3.5 (AUC, 0.746; 95% CI, 0.607–0.885). Using the optimal LPR cutoff value of 0.47, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 84.1, 66.7, 88.3, 58.3, and 79.8%, respectively. Multivariate analysis by logistic regression showed that LPR was an independent predictor for LN metastasis (odds ratio, 6.45; 95% CI, 1.785–23.301; P = 0.004). In the subgroup analysis of adenocarcinoma patients (n = 18; 32 LNs), TLG3.5 was a better predictor (AUC, 0.816; 95% CI, 0.639–0.985) than LPR (AUC, 0.792; 95% CI, 0.599–0.986) or LN SUVmax (AUC, 0.792; 95% CI, 0.625–0.959). CONCLUSIONS: Our findings suggest that LPR on FDG-PET is a useful predictor for LN metastasis in patients with cN2 NSCLC. TLG can be a good predictor for LN metastasis in patients with adenocarcinoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08688-6. BioMed Central 2021-09-02 /pmc/articles/PMC8414769/ /pubmed/34474680 http://dx.doi.org/10.1186/s12885-021-08688-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Nakanishi, Keita
Nakamura, Shota
Sugiyama, Tomoshi
Kadomatsu, Yuka
Ueno, Harushi
Goto, Masaki
Ozeki, Naoki
Fukui, Takayuki
Iwano, Shingo
Chen-Yoshikawa, Toyofumi Fengshi
Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer
title Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer
title_full Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer
title_fullStr Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer
title_full_unstemmed Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer
title_short Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer
title_sort diagnostic utility of metabolic parameters on fdg pet/ct for lymph node metastasis in patients with cn2 non-small cell lung cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414769/
https://www.ncbi.nlm.nih.gov/pubmed/34474680
http://dx.doi.org/10.1186/s12885-021-08688-6
work_keys_str_mv AT nakanishikeita diagnosticutilityofmetabolicparametersonfdgpetctforlymphnodemetastasisinpatientswithcn2nonsmallcelllungcancer
AT nakamurashota diagnosticutilityofmetabolicparametersonfdgpetctforlymphnodemetastasisinpatientswithcn2nonsmallcelllungcancer
AT sugiyamatomoshi diagnosticutilityofmetabolicparametersonfdgpetctforlymphnodemetastasisinpatientswithcn2nonsmallcelllungcancer
AT kadomatsuyuka diagnosticutilityofmetabolicparametersonfdgpetctforlymphnodemetastasisinpatientswithcn2nonsmallcelllungcancer
AT uenoharushi diagnosticutilityofmetabolicparametersonfdgpetctforlymphnodemetastasisinpatientswithcn2nonsmallcelllungcancer
AT gotomasaki diagnosticutilityofmetabolicparametersonfdgpetctforlymphnodemetastasisinpatientswithcn2nonsmallcelllungcancer
AT ozekinaoki diagnosticutilityofmetabolicparametersonfdgpetctforlymphnodemetastasisinpatientswithcn2nonsmallcelllungcancer
AT fukuitakayuki diagnosticutilityofmetabolicparametersonfdgpetctforlymphnodemetastasisinpatientswithcn2nonsmallcelllungcancer
AT iwanoshingo diagnosticutilityofmetabolicparametersonfdgpetctforlymphnodemetastasisinpatientswithcn2nonsmallcelllungcancer
AT chenyoshikawatoyofumifengshi diagnosticutilityofmetabolicparametersonfdgpetctforlymphnodemetastasisinpatientswithcn2nonsmallcelllungcancer